Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone

FIGURE 1. Independent determinants of total thrombotic events. Baseline patient and procedural characteristics associated with arterial and venous thrombotic risk after multivariate modeling are shown. Candidate variables shown in Figure S1. ABI, ankle‐brachial index; BP, blood pressure; CAD, coronary artery disease; CI, confidence interval; CLI, chronic limb ischemia; eGFR, estimated glomerular filtration rate; HR, hazard ratio

FIGURE 2. First and total arterial and venous thrombotic events, per 100 patient‐years. The first and total arterial and venous thrombotic events per 100 patient years in the Placebo and Rivaroxaban groups, respectively, are provided. ARR, absolute risk reduction; CI, confidence interval; HR, hazard ratio; p, p‐value; p‐y, patient‐yearsNote: arterial and venous events include acute limb ischemia, major amputation of vascular cause, MI, ischemic stroke, and symptomatic VTE (deep vein thrombsis and pulmonary embolism).

FIGURE 3. Second Arterial and Venous Thrombotic Events by Type of First Nonfatal Event. The number of second thrombotic events by type of first nonfatal event, categorized by arterial and venous and by treatment group, are presentedNote: Of the 929 patients with first events, all but 4 were nonfatal. Arterial and venous events include acute limb ischemia, major amputation of vascular cause, MI, ischemic stroke, and symptomatic VTE (deep vein thrombsis and pulmonary embolism).

FIGURE 4. Distribution of total (first and subsequent) arterial and venous thrombotic events. The distribution of first, second, and third and subsequent arterial and venous thrombotic events within the placebo and rivaroxaban‐treated groups is shown, along with the occurrence of the nonfatal outcome components and fatal events

FIGURE 5. Effect of rivaroxaban on arterial and venous thrombotic events. Shown are the cumulative incidence curves for the composite first and total arterial and venous thrombotic events, defined as acute limb ischemia, major amputation of vascular etiology, myocardial infarction, ischemic stroke, or symptomatic VTE, in patients randomized to placebo versus rivaroxaban. The treatment hazard ratios (HRs) for first and total events and associated 95% confidence intervals (CIs) are provided, along with the estimated rates at 3 years and associated 95% CIs, and the absolute risk reductions (ARR) in terms of the number of thrombotic events per 100 patients prevented with associated 95% CIs. p, p‐value